Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Global Blood Therapeutics, Inc. (GBT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2022 8-K Resignation/termination of a director
Docs: "First Supplemental Indenture, between Global Blood Therapeutics, Inc. and U.S. Bank Trust Company, National Association, as trustee"
09/30/2022 8-K Submission of Matters to a Vote of Security Holders, Other Events  Interactive Data
09/23/2022 8-K Other Events  Interactive Data
08/08/2022 8-K Quarterly results
07/26/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "MHRA Grants Marketing Authorization for GBT’s Oxbryta® for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older Voxelotor is the first medicine approved in Great Britain to directly inhibit sickle hemoglobin polymerization, the underlying molecular cause of sickle cell disease"
07/14/2022 8-K Quarterly results
06/29/2022 8-K Quarterly results
06/15/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
06/06/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
03/25/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/23/2022 8-K Quarterly results
Docs: "GBT Reports Fourth Quarter and Full Year 2021 Financial Results"
02/16/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "European Commission Approves Oxbryta® for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older The first sickle hemoglobin polymerization inhibitor approved in Europe, Oxbryta increases hemoglobin levels and reduces sickling and hemolysis – the cause of long-term complications of sickle cell disease"
01/27/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Positive Early Access to Medicines Scheme Scientific Opinion Awarded to GBT’s Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease LONDON, Jan. 27, 2022 -- Global Blood Therapeutics today announced that the UK’s Medicines and Healthcare products Regulatory Agency has awarded a positive scientific opinion under the Early Access to Medicines Scheme for voxelotor, an oral once-daily tablet under review by the MHRA for the treatment of haemolytic anaemia due to sickle cell disease in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide. This positive opinion means that those patients living with SCD and meeting the eligibility criteria can gain early, pre-license access to voxelotor, while the MHRA completes its..."
01/10/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Oxbryta® Tablets for Oral Suspension, A New Dispersible Tablet Dosage Form, Now Available for Patients with Sickle Cell Disease in the United States"
12/17/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Indenture, between Global Blood Therapeutics, Inc. and U.S. Bank National Association, as trustee",
"Form of Capped Call Transaction Confirmation"
12/17/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "U.S. FDA Approves Supplemental New Drug Application for Expanded Indication of Oxbryta® for Children as Young as 4 Years of Age with Sickle Cell Disease"
12/17/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "GBT’s Oxbryta® Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older"
12/15/2021 8-K Quarterly results
12/14/2021 8-K Quarterly results
12/13/2021 8-K Quarterly results
12/13/2021 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "GBT Reports Third Quarter 2021 Financial Results"
11/04/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "GBT Announces Six Data Presentations on Sickle Cell Disease at Upcoming 63rd American Society of Hematology Annual Meeting & Exposition"
09/07/2021 8-K Quarterly results
08/03/2021 8-K Quarterly results
Docs: "GBT Reports Second Quarter 2021 Financial Results"
07/22/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "GBT Provides Regulatory and Pipeline Updates in Sickle Cell Disease"
06/17/2021 8-K Quarterly results
06/14/2021 8-K Quarterly results
06/11/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy